## IQV: IQVIA Holdings, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.05 indicates fundamental undervaluation. Quality metrics strong (ROE 19%). Consistent execution (4/4 quarters beat estimates). Caution: momentum weakening (-2.5% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($211.89)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 7
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. IQVIA (NYSE:IQV) Cut to "Hold" at Wall Street Zen**
- Source: MarketBeat | 20251206T072220 | Neutral | Relevance: 99%
- Wall Street Zen downgraded IQVIA (NYSE: IQV) from "buy" to "hold," despite the company slightly beating Q3 earnings estimates with $3.00 EPS and $4.10B revenue, and setting FY2025 guidance at 11.850â€“11.950 EPS. The stock trades with a market cap of $38.4 billion and has an average price target of $241.44 from analysts, who overall maintain a "Moderate Buy" rating. Insider activity shows a sale of 4,000 shares by Eric Sherbet, while institutional ownership stands at 89.6%.

**2. Fisher Asset Management LLC Sells 10,975 Shares of IQVIA Holdings Inc. $IQV**
- Source: MarketBeat | 20251207T040920 | Somewhat-Bullish | Relevance: 99%
-  Fisher Asset Management LLC significantly reduced its stake in IQVIA Holdings Inc. (NYSE:IQV) by 55.1% in the second quarter, selling 10,975 shares and leaving it with 8,950 shares valued at approximately $1.41 million. Despite this, IQVIA reported strong quarterly earnings, beating estimates and providing optimistic FY2025 guidance, leading analysts to maintain a "Moderate Buy" rating with an average target price of $241.44. Institutional investors collectively own 89.62% of the company, with various firms increasing their positions during the quarter.

**3. North Growth Management Ltd. Invests $5.22 Million in IQVIA Holdings Inc. $IQV**
- Source: MarketBeat | 20251208T122519 | Bullish | Relevance: 99%
-  North Growth Management Ltd. recently purchased a new stake of 33,000 shares in IQVIA Holdings Inc. (NYSE:IQV), valued at approximately $5.22 million. This move is part of broader institutional investor activity, with several other firms increasing their holdings in the medical research company. The article also notes recent insider stock sales and provides an overview of analyst ratings and IQVIA's financial performance.

**4. IQVIA Holdings Inc. $IQV Shares Sold by Quantbot Technologies LP**
- Source: MarketBeat | 20251209T120812 | Somewhat-Bullish | Relevance: 99%
-  Quantbot Technologies LP significantly reduced its stake in IQVIA Holdings Inc. ($IQV) by 54.3% in the second quarter, selling 8,552 shares and retaining 7,206 shares valued at approximately $1.14 million. Despite this, institutional investors collectively own about 89.62% of the company's stock, with several other firms increasing their positions. IQVIA recently exceeded Q2 earnings and revenue expectations, reporting $3.00 EPS and $4.10 billion in revenue, and analysts maintain a "Moderate Buy" rating with a target price of $241.44.

**5. Invesco Ltd. Reduces Stock Holdings in IQVIA Holdings Inc. $IQV**
- Source: MarketBeat | 20251206T113159 | Neutral | Relevance: 98%
- Invesco Ltd. has reduced its stake in IQVIA Holdings Inc. (NYSE:IQV) by 3.7% during the second quarter, now owning 2,406,780 shares valued at approximately $379 million. Despite this reduction, other institutional investors have increased their holdings in IQVIA. The company's stock shows a market capitalization of $38.43 billion, with analysts maintaining a "Moderate Buy" rating and a consensus target price of $241.44.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | Morgan Stanley | $265 | $250 | +6% |
| 2025-11-13 | BMO Capital | $260 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | Morgan Stanley | main | Overweight |
| 2025-11-13 | BMO Capital | init | Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 5 ($1.46M) |
| Sells | 1 ($5.78M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 46.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 11.4% (-0.9%)
- Blackrock Inc.: 8.7% (+4.5%)
- Harris Associates L.: 6.7% (-3.1%)
- State Street Corpora: 4.4% (-1.0%)
- JPMORGAN CHASE & CO: 3.9% (+110.0%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-2.5% 5d) with bearish MACD, trend may be turning.
2. Insider selling cluster: $5.8M in recent transactions.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.05 suggests fair value with growth premium. Analyst sentiment positive (1 raises, avg +6%). Insider selling cluster ($5.8M in 90 days), potential headwind. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $38.1B |
| Beta | 1.37 |
| 52W Range | $134.65 - $234.30 |
| Short Interest | 3.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.05 |
| Forward P/E | 17.3 |
| Current P/E | 18.8 |
| YoY Growth | 8.7% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 0.6% to -1.9% (-2.5% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 5.9pp (needs >4.0% for momentum thesis). Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram bearish (-0.72), momentum weakening. RSI neutral at 54. Elevated volume (1.5x 20MA), institutional activity likely.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -1.93% (CS: 40) | Neutral |
| RSI_14 | 54.3 | Neutral |
| MACD Histogram | -0.72 | Bearish |
| vs SMA20 | 1.001x | Above |
| vs SMA50 | 1.043x | Above |
| vs SMA200 | 1.237x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $223.57
- **Stop Loss:** $211.89 (5.2% risk)
- **Target:** $246.93 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 42
- **Position Value:** $9,389.94
- **Portfolio %:** 9.39%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

### Earnings

**Next:** 2026-02-05 (Est: $3.40)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.98 | $3.00 | +0.8% |
| 2025Q2 | $2.77 | $2.81 | +1.4% |
| 2025Q1 | $2.63 | $2.70 | +2.6% |
| 2024Q4 | $3.11 | $3.12 | +0.4% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*